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Abstract
Grade II gliomas are slowly growing primary brain tumors that affect mostly young patients.
Cytotoxic therapies (radiotherapy and/or chemotherapy) are used initially only for patients
having a bad prognosis. These therapies are planned following the “maximum dose in mini-
mum time” principle, i. e. the same schedule used for high-grade brain tumors in spite of
their very different behavior. These tumors transform after a variable time into high-grade
gliomas, which significantly decreases the patient’s life expectancy. In this paper we study
mathematical models describing the growth of grade II gliomas in response to radiotherapy.
We find that protracted metronomic fractionations, i.e. therapeutical schedules enlarging the
time interval between low-dose radiotherapy fractions, may lead to a better tumor control
without an increase in toxicity. Other non-standard fractionations such as protracted or
hypoprotracted schemes may also be beneficial. The potential survival improvement
depends on the tumor’s proliferation rate and can be even of the order of years. A conserva-
tive metronomic scheme, still being a suboptimal treatment, delays the time to malignant
progression by at least one year when compared to the standard scheme.
Introduction
Gliomas are the most frequent type of primary brain tumors. Patients diagnosed with gliomas
typically die because of the complications related to the disease. No substantial progress has
been made in the last decades, thus these types of cancer remain to be a major challenge for
medicine.
Low-grade gliomas (LGG) are a subgroup of gliomas (WHO grade II primary brain
tumors) usually having slow growth and moderate incidence that are diagnosed mostly in
young adults. The median survival time for LGG patients is about 5 years after diagnosis [1, 2].
After a variable time, these tumors undergo the so-called malignant transformation (MT) and
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progress, to a higher-grade tumor (HGG). After the MT, the neurological symptoms and com-
plications become more difficult to handle and the mean patient’s survival time decreases
significantly.
Many LGG patients present few, if any, neurological symptoms for extended periods of
time. The use of surgery on diagnosis results in a better outcome and is now the default option
in many centers [3–5]. However, the decision on the timing and specific combination of resec-
tion, radiation therapy (RT), and/or chemotherapy use on each patient is a complex one. Typi-
cally, it is based on the consideration of many variables including age, performance status, and
location of tumor [2, 6]. Since LGGs are such a heterogeneous group of tumors with variable
natural histories, the risks and benefits of each therapy must be carefully balanced.
In this paper we focus our attention on RT. It is known that RT is beneficial for the patient
in terms of survival [7]. It is now well known that immediate RT after surgery increases the
progression-free survival, but does not improve overall survival [8]. Although conformal tech-
niques are decreasing the amount of radiation received by the surrounding normal brain tissue
this therapy may induce serious long term neurological deficits. Currently, RT is usually
offered to patients with a combination of poor risk factors such as age, sub-total resection, dif-
fuse astrocytoma pathology [9], or those suspicious of having a high grade tumor.
Mathematical modeling has the potential to help in finding the optimal timing for radiation
therapy and in developing optimal fractionation schemes for selected patient subgroups.
Although some studies on non-standard fractionations have been developed in clinical settings
[10], they have been very limited. Moreover, the availability of high resolution magnetic reso-
nance images allowing the quantitative measurements of tumor growth rates (and other geo-
metrical imaging biomarkers) may provide key information for the development and validation
of such models [11].
Mathematical research on gliomas has been very extensive although much focused on the
more frequent HGGs [12–28]. Most of these models are based on the Fisher-Kolmogorov
equation [29] to be described in detail later and add different layers of complexity depending
on the level of biological detail incorporated into the model. As to RT, it has been studied
mathematically both in the context of HGGs [30–35] and LGGs [36–40].
Ribba et al [36] developed a model based on ordinary differential equations describing the
response of LGGs to different therapies with a number of undetermined parameters that can
be fit to describe the individual patient’s response with a good qualitative agreement. More
recently, Pérez-Garcı́a et al [37] constructed a simple spatial model able to describe the known
phenomenology of the response of LGGs to RT including the observations from Pallud et al
[41]. An alternative explanation to the phenomenon has been developed by Badoual et al [40]
using an oedema-based model. Galochkina et al [38] found that small variations of the stan-
dard dose distributions and/or changes in the fractionation led only to minor improvements
at best, in agreement with clinical experience.
In clinical practice, radiation doses are given in a very short period of time with the purpose
of killing every clonogenic cell without allowing the tumor to regrow between fractions [42].
In fact, the most typical course of RT for LGGs consists of 30 doses of 1.8 Gy given from Mon-
day to Friday for 6 weeks. This is a reasonable practice when radiation therapy is used with
curative intent and/or in fast-growing tumors. However, it is not obvious that the optimal frac-
tionation should follow the same scheme when used on a radioresistant tumor. LGGs grow
slowly, with a very low number of mitoses seen per field which means that only a small fraction
of tumor cells is proliferating at a given time. Typical numbers for LGG are usually around 4%
of the tissue showing positivity for proliferation markers as measured by Ki-67/MIB-1 immu-
nostaining [43, 44]. Thus, if only few cells are dividing, it may be reasonable to enlarge the dis-
tance between fractions. i.e. to resort to a protracted therapeutical scheme, to allow for more
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tumor cells to enter in the cell cycle rendering radiation fractions more effective. This idea was
explored by Pérez-Garcı́a and Pérez-Romasanta [39]. The authors fixed the dose per fraction
to be the one used in practice but left free the time intervals between fractions. They found a
potential improvement in survival by using a protracted regime with dose time inter-spacing
between one and two months.
To fix notation we will refer to treatment schemes with spacing between fractions smaller/
larger than one day as accelerated/protracted. Also treatment schemes with dose per fraction
smaller or larger than 1.8 Gy are referred to as hyperfractionated or hypofractionated respec-
tively. The special case of hyperfractionated therapies with time separation between fractions
larger than the standard could be denoted as hyperprotracted if we follow the established nam-
ing convention. However, it is customary to refer to these protocols as metronomic. Fig 1 sum-
marizes different potential schemes to be considered later in this paper.
In this paper we discuss non-standard radiotherapy fractionations potentially deferring the
most the time to the malignant transformation (TMT) of the LGG into a HGG. One of the
driving forces of the MT may be the increase in mutation rates originated by alterations of the
tumor micro-environment. These changes could be driven by the continuous cell density
growth that ultimately lead to vessel damage, generation of hypoxic foci, the stabilization of
hypoxia dependent signaling molecules such as hypoxia inducible factor-1α (HIF-1α) and the
increase of genomic instability [24, 45–47] (see Fig 2).
To accomplish the task of finding the optimal therapy in this paper we took the dose per
fraction, the time between fractions and the number of fractions to be free parameters. We
intended the toxicity of the novel schemes to be the same (or lower) than that of the schemes
Fig 1. Radio(chemo)-therapy schemes classified by the dose per fraction and the time spacing between fractions. All schemes are defined in
relation to the standard one.
https://doi.org/10.1371/journal.pone.0178552.g001
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currently in use. Thus, the number of doses was taken to be a function of the chosen toxicity
and the dose per fraction. This means that we consider finding novel RT fractionations
schemes by changing two independent variables: the dose per fraction and time interval
between fractions.
Materials and methods
Equations for the evolution of the cell density
The dynamics of tumor cells was described mathematically in this study using the Fisher-Kol-
mogorov equation [29]
@u
@t
à Dr2uá rÖ1  uÜu: Ö1Ü
Eq (1) accounts for the growth of a spatio-temporal density u(x, t) of tumor cells in units
of a maximal cell number. Tumor cells proliferate with a typical time 1/ρ and have a character-
istic mobility (diffusion) coefficient D. This model has been used extensively to describe the
dynamics of gliomas and as the basis to construct models of response to RT [33] and specifi-
cally for LGGs [39]. Other more complicated models for LGGs keep the same structure for the
tumor cell compartment while incorporating a second compartment for a different quantity
related to the radiological response, either dying cells [37, 38] or edema [40], that does not
affect the response to the therapy.
The model equations are considered in a three dimensional domain O of the brain supple-
mented with initial data u0 2 C2ÖOÜ, and no-flux boundary conditions. It is possible to write
an equation for an upper bound for the tumor amplitude U(t), 0 u(x, t) U(t) that is [39]
dU
dt
à rÖ1  UÜU Ö2Ü
with U(0) = U0 as the initial maximum tumor cell density in the tissue. In addition to provid-
ing an upper bound for the tumor cell density. Eq (2) has also been shown to describe the evo-
lution of the tumor amplitude
AÖtÜ à max
x2O
uÖx; tÜ Ö3Ü
with good accuracy in one-dimensional scenarios [37].
Fig 2. The increase of celularity may lead to the malignant transformation of LGGs. Left and right images are immunohistochemical staining for
Hematoxilyn and Eosin for LGG and HGG biopsies respectively.
https://doi.org/10.1371/journal.pone.0178552.g002
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Mathematical description of radiation therapy
To include radiation therapy in the model, we used the classical linear-quadratic (LQ) model
[42]. Thus, for a radiation dose dj given at a time tj, we took the survival fraction Sf(dj), i.e. the
fraction of cells that are not lethally damaged to be given by
Sf ÖdjÜ à e
 at dj bt d2j Ö4Ü
The parameters αt and βt are the linear and quadratic coefficients for tumor cell damage of the
LQ model.
Eq (4) does not account for the time dynamics of the tumor and DNA damage during each
radiation fraction, thus the effect of RT was assumed to be instantaneous. This is so because
RT is given in a time (typically about 10 minutes) that is very short in comparison with typical
cellular proliferation times in LGGs [37]. Repair processes occur in the time-scale of minutes
or a few hours, which is negligible for the very long evolution times of LGGs.
The full treatment consists of a total dose, D, split in a series of N radiation fractions
with doses per fraction {dj}j = 1,      , N, such that d1 +       + dN = D, given at irradiation times
{tj}j = 1,      , N. The tumor amplitude U(t) at the irradiation times satisfies.
UÖtáj Ü à Sf ÖdjÜUÖt j Ü Ö5Ü
Damage to normal tissue (or toxicity/standard toxicity) caused by RT can be estimated using
Eq (4) but with the parameters corresponding to the healthy tissue αh, βh, with αh/βh⇡ 2 [42]:
EÖN; d1; . . . ; dNÜ à   ln
YN
jà1
Sf ÖdjÜ
" #
à ah Dá
1
ah=bh
XN
jà1
d2j
 !
Ö6Ü
In addition, acute tissue reactions and other side effects depend: (i) on the total volume irra-
diated (the so-called volume effect) and (ii) on the maximal dose per fraction d⇤ used. We did
not consider in this paper spatial aspects of radiation therapy or other complications and thus
will assume that all tumor cells within the tumor receive the same amount of radiation.
Time to malignant transformation
One of the driving forces of the MT is the increase in mutation rates originated by micro-envi-
ronmental alterations. These changes are due to the fact that the cell density increase leads to
vessel damage, generation of hypoxic foci, stabilization of hypoxia dependent signaling mole-
cules such as HIF-1α and an increase in genomic instability [45–47]. Previous studies have
reported the role of hypoxia as triggering the MT of oral sub mucous fibrosis [48]. Several
mathematical models of gliomas, which are consistent with experimental facts, have also dis-
cussed that high density cell foci may lead to the MT of LGGs [22, 24].
Thus, we assumed that the tumor shows LGG features while the maximum tumor density is
below a critical level U⇤. On the basis of that we define the TMT as the time when the tumor
amplitude (U) reaches the critical threshold (U⇤).
Optimization problem
In this paper our goal was to choose the therapy in order to make TMT as large as possible
when the dose per fraction, the number of fractions and the time between them are treated
as free parameters restricted to a constant toxicity. We considered the dose per fraction
and the time between fractions to be fixed during the full radiation course, that is dj = d and
tj − tj−1 = Δ, 8j 2 {1, . . ., N}, where N is the total number of fractions. In that case, we computed
Non-standard radiotherapy fractionations delay the time to malignant transformation of LGG
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explicitly the TMT using the exact solution of Eq (2) and the recursion formula Eq (5), thus
TMT is obtained to be
TMTÖN;D; dÜ à ND|{z}
treatment time
á 1
r
log
U⇤Ö1  UNÖdÜÜ
UNÖdÜÖ1  U⇤Ü
  
|ÇÇÇÇÇÇÇÇÇÇÇÇÇÇÇÇÇÇ{zÇÇÇÇÇÇÇÇÇÇÇÇÇÇÇÇÇÇ}
regrowth time
Ö7Ü
where UN is the tumor amplitude at time NΔ (end of treatment) given by
UNÖdÜ à
U0ÖaSf ÖdÜÜ
N
1á U0Öa  1Ü
ÖaSf ÖdÜÜN 1
aSf ÖdÜ 1
h i Ö8Ü
and α = exp(ρN), provided UN/Sf U⇤. This restriction is necessary to ensure that U(t) is
below the critical threshold U⇤ during the treatment.
The restriction that the toxicity due to the optimal therapy should be smaller or equal than
the obtained by the standard treatment, means that
Eopt à EÖNopt; doptÜ  Eh à EÖN à 30; d à 1:8GyÜ; Ö9Ü
with Eopt given by Eq (6). Thus, for every choice of d we choose the number of doses N to sat-
isfy
N à Eh
ah
1
d á ahd2=bh
  ⌫
Ö10Ü
In addition to the biologically motivated constraints, a minimum dose per fraction of 0.5
Gy was set to avoid situations involving an excessive number of RT sessions.
Parameter estimation
Proliferation rates for LGGs (ρ) have been estimated to be around 0.003 day−1 in previous
works [19, 22, 37, 40] which gives a doubling time of the order of one year. From the most
indolent tumors to those more aggressive within the class of LGGs the full range may comprise
an order of magnitude, that is from 0.002 day−1 to 0.01 day−1.
As to the cell density parameters U0 and U⇤, the normal brain tissue has low cellularity and
the cell density leading to symptoms (U0) is probably dependent on the location of origin of
the tumor. However, most LGGs are supratentorial and appear in the white matter. We will
take the initial density U0 to be around 0.3 which means that symptoms arise when 30% of the
space is occupied by tumor cells, a number well beyond the normal physiological value that
may be around 10-15% (for non-pathological cells). We took the maximal tissue density lead-
ing to irreversible damage U⇤ to be around 0.5-0.65 [39] which corresponds to the maximal
cell density that tissue is able to support without substantial changes to the microenvironment.
Since both U⇤ and U0 may have a range of variation, we performed a study of the influence of
these parameters on our results.
In addition, it is known that gliomas are radio-resistant tumors with high surviving frac-
tions in vitro and mixed response to radiation in vivo. We will use here the approach of [37]
that estimated the surviving fraction for doses of 1.8 Gy from the radiological response fitting
typically observed dynamics of mean tumor diameters from [41]. This gives survival fractions
Sf(1.8) in the range of 0.8-0.9. Taking the values of the radiobiological parameters for LGG to
be αt = 0.0564Gy
−1 and βt = 0.0188 Gy
−2 we get Sf(1.8) = 0.85 and the ratio αt/βt = 3Gy in agree-
ment with the known values for this paramater. [42].
Non-standard radiotherapy fractionations delay the time to malignant transformation of LGG
PLOS ONE | https://doi.org/10.1371/journal.pone.0178552 June 1, 2017 6 / 19
It is worth to remark that only the ratio αh/βh is necessary to compute Eh. The ratio for
healthy brain tissue, αh/βh, is about 10 Gy [42]. Moreover, small variations of this choice did
not affect our results.
The parameters used through this paper are summarized in (Table 1).
Results
The time to malignant transformation depends on the fractionation
scheme and tumor’s proliferation rate
Representative examples of our numerical simulations for the TMT under different frac-
tionation schemes are shown in Fig 3. Specifically we present results for proliferation rates:
ρ = 0.01 day−1 (fast-growing tumor, Fig 3(a)) and ρ = 0.005 day−1 (slowly-growing tumor,
Fig 3(b)).
Table 1. Values of the biological and clinical parameters used in the mathematical model of LGG evolution.
Variable Description Value (units) References
ρ Proliferation rate 0.002-0.01 day−1 [37, 38, 40]
d Dose per fraction 0.5-3.2 Gy [42]
Sf(1.8) Survival fraction 0.85 [42]
U0 Initial cell density 0.1-0.3 [39]
U* Critical cell density 0.5-0.65 [39]
αt/βt LGG ratio 3 Gy [42]
αt Linear damage to LGG 0.0564 Gy−1 Estimated
αh/βh Ratio for normal brain 10 Gy [42]
https://doi.org/10.1371/journal.pone.0178552.t001
Fig 3. Results for the TMT under different fractionation schemes. Stars and circles indicate the location of the standard and optimal treatments
respectively on the (Dose, Δ) plane and their associated TMT. (a) ρ = 0.01 day−1. Optimal fractionation is dopt = 0.5 Gy every 6 days (Δopt = 6 days),
and TMT = 2.9 years. (b) ρ = 0.005 day−1. Optimal fractionation is dopt = 0.5 Gy and Δopt = 16 days TMT = 5.7 years.
https://doi.org/10.1371/journal.pone.0178552.g003
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For every ρ in the range 0.002-0.01 day−1, we obtained that choosing the optimal dose, dopt,
to be equal to 0.5 Gy, and the optimal time between fractions (Δopt) being more than one day,
led to the longest TMT. Thus, metronomic scheduling was found to be the optimal one for
every proliferation value, these results can be observed in Fig 3. For fast-growing LGGs with ρ =
0.01 day−1, the optimal inter-spacing (Δopt) was found to be 6 days, Fig 3(a). For slowly-growing
LGGs with ρ = 0.005 day−1, Δopt = 16 days, Fig 3(b). These findings point to a dependence of the
optimal time spacing between doses on the proliferation rate to be analyzed later in this section.
Hence, the optimal therapy would be the one with fixed dose equal to 0.5 Gy and its corre-
sponding Δopt.
The predicted TMT for the standard scheme is 1.6 years for fast-growing LGG typical parame-
ters (ρ = 0.01 day−1) and 3.3 years for slowly growing LGG (ρ = 0.005 day−1). Using the optimal
therapeutical schedulings led to TMT = 2.9 years (ρ = 0.01 day−1) and TMT = 5.7 years (ρ = 0.005
day−1) respectively. Thus providing prolonged survivals beyond 70% of the initial times.
Pérez-Garcı́a and Pérez-Romasanta [39] predicted that protracted schemes would lead to a
delay of the MT, which is consistent with our results (see Fig 3). Indeed, enlarging the time
interval between doses was always beneficial when comparing to the standard therapy pro-
vided the interval is not larger than the corresponding Δopt. On the basis of the results shown
in Fig 3 it is clear that both protracted and hypoprotracted therapies delay malignant transfor-
mation although the largest gain was obtained for the metronomic schemes.
There is little or no advantage in using hyper or hypofractionated schemes. This is also con-
sistent with the results by Galochkina et al [38], who found that small variations from the stan-
dard scheme did not result in significant delays of the TMT.
The choice of the time spacing between fractions Δ is critical in getting a substantial delay
of the TMT. Indeed, if Δ is taken to be larger than the optimal one, Δopt, the therapy becomes
useless with very small survival gains (blue upper left regions in Fig 3(a) and 3(b)). In that situ-
ation, the tumor reaches the critical threshold, U⇤, before completing the treatment. So, in this
case, the treatment is not able to maintain the tumor under control and would affect instead
the faster growing HGG tumor. Thus although that choice would be unable to delay optimally
the MT it would provide some therapeutical benefit of the order of the one currently obtained
when treating trasformed HGG tumors.
Optimal treatments control tumor growth below the cell density threshold
for the MT
Fig 4 compares the tumor amplitude (maximum cell density) evolution for the standard versus
the optimal fractionations for (a) a fast growing and (b) a slowly growing LGG. The variations
observed in the TMT can be explained by Eq (7). The larger the time interval between doses is,
the longer the TMT.
Standard fractionation leads to a substantial initial decrease of the amplitude and a subse-
quent tumor regrowth. Metronomic therapies instead intend to maintain the tumor cell den-
sity under the critical threshold for as long as the treatment can be maintained. Thus, the
standard therapy is more efficient in reducing the total tumor load for a shorter period of time.
However, a complete elimination of the tumor load is known to be unlikely due to the radio
resistance of glioma cells.
TMT using optimal therapies does not depend on the initial cell density
U0, but on the critical threshold density U*
We studied the impact of the initial cell density, U0 and the critical threshold, U⇤, on the TMT
under the optimal fractionation scheme. To do so, we chose four different sets of parameters
Non-standard radiotherapy fractionations delay the time to malignant transformation of LGG
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(U0, U⇤) as follows: First, we fixed U⇤ and chose two different U0 values and, then, we fixed
U0 and chose two different U⇤ values. For each set, we performed two simulations, one for
ρ = 0.01 day−1 and, other for ρ = 0.005 day−1. These results are summarized in Fig 5.
In our simulations, the initial tumor density did not have a substantial effect on the TMT
under optimal therapies (cf. Fig 5(a) and 5(b)). However, the critical density U⇤ had a strong
influence on the TMT (cf. Fig 5(c) and 5(d)).
A study of the full parameter space Δopt(U0, U⇤), TMT(U0, U⇤) for several values of ρ was
performed to confirm the results. Fig 6 presents an example that confirms the previous find-
ings. Both the optimal fractionation and TMT where independent of U0 but dependent on U⇤.
Fig 7 shows the dependence of the optimal protocol (Δopt) on U⇤ for two different prolifera-
tion values. The dependence on U⇤ of the fractionation parameters was also linked to the pro-
liferation rate. In Fig 7 we plotted the TMT and the time between fractions as a function of the
threshold, U⇤.
Fig 4. Evolution of the tumor amplitude under standard and optimal therapies (black and gray curves respectively). The value of the
parameters used are: U0 = 0.3, U* = 0.65 and (a) ρ = 0.01 day−1 (a fast-growing virtual LGG) and (b) ρ = 0.005 day−1 (a slowly growth virtual LGG).
https://doi.org/10.1371/journal.pone.0178552.g004
Non-standard radiotherapy fractionations delay the time to malignant transformation of LGG
PLOS ONE | https://doi.org/10.1371/journal.pone.0178552 June 1, 2017 9 / 19
Fig 5. Tumor amplitude evolution for eight virtual tumors under the effect of the optimal radiation
treatment. (a) ρ = 0.01 day−1, U* = 0.6. (b) ρ = 0.005 day−1, U* = 0.6. (c) ρ = 0.01 day−1, U0 = 0.3. (d) ρ =
0.005 day−1, U0 = 0.3. (a-b) Show the comparison between two simulations with U0 = 0.15 and U0 = 0.3 under
optimal therapies. (c-d) Show the comparison between two simulations with U* = 0.5 and U* = 0.65 under
optimal therapies.
https://doi.org/10.1371/journal.pone.0178552.g005
Non-standard radiotherapy fractionations delay the time to malignant transformation of LGG
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Metronomic therapies provide substantial survival advantages for virtual
patients
In order to quantify the delay in TMT obtained from the optimal metronomic fractionations
we performed several series of simulations. First, we fixed U0 = 0.3 and U⇤ = 0.5 as discussed in
previous works [39] and computed Δopt and the corresponding TMT as a function of ρ. This
was done for both the optimal parameters and the standard fractionation (N = 30, Δ = 1 and
d = 1.8Gy).
The results for Δ and TMT are shown in Fig 8(a). The comparison between the TMT for
the standard and optimal fractionation and the difference between them are shown in Fig 8(b).
Fig 6. Dependence of the optimalΔ, (Δopt) and TMT on the initial and critical tumor cell densities for ρ = 0.005 day−1. (a) Δopt as a function of U0
and U*. (b) TMT computed using the optimal Δopt(U0, U*). The insets show the curves for U0 = 0.3.
https://doi.org/10.1371/journal.pone.0178552.g006
Fig 7. Dependence of the TMT andΔopt on U* for U0 = 0.3. (a) ρ = 0.01 day−1, (b) ρ = 0.005 day−1. In both cases, the optimal fractionation for each
parameter set was used.
https://doi.org/10.1371/journal.pone.0178552.g007
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The time delay of the malignant transformation is substantial and even of the order of several
years for slowly growing tumors. In general, the TMT delay was found to be larger in absolute
numbers for slowly growing tumors but it was always very substantial in percent terms
(around 80-90%) for fast growing LGGs.
Protracted and hypoprotracted schemes delay substantially the
malignant transformation
Although hypoprotracted and protracted schemes are suboptimal therapies, they substantially
delayed the malignant transformation in-silico from one year (for fast-growing tumors) to
three years (for slowly-growing tumors). Some examples are shown in Fig 9. Thus, large
parameter regions in the plane (Δ, d) provide therapeutical schemes better than the standard
one. In many cases the TMTs obtained are close to the optimal ones (Fig 9).
Fig 8. The optimal protocol delays substantially the MT considering the optimal time between fractionsΔopt for U0 = 0.3, U* = 0.5 and ρ 2
[0.002, 0.01]. (a) Δopt and TMT obtained with the optimal protocol. (b) TMT for both the optimal (black curve) and the standard protocols (dark gray
curve). The light gray curve represents the differences between their TMTs. The later provides a quantification of the benefit obtained from the optimal
fractionation over the standard one.
https://doi.org/10.1371/journal.pone.0178552.g008
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A conservative suboptimal scheme improves standard treatment results
for any proliferation rate
If it were possible to know the specific parameters ρ and U⇤ for each patient our model could
suggest the best personalized optimal therapy. However, this is a very challenging task. Thus, it
may be preferable to find a suboptimal RT scheme improving the standard treatment results
for all LGG patients.
A possibility was found by using the optimal treatment for fast-growing LGGs, specifically
the one presented in Fig 3(a) (dopt = 0.5Gy and Δopt = 6 days). Fig 10 shows that the new
scheme improves the results of the standard one for any value of 0.002 ρ 0.01.
Fig 9. Comparison of four different fractionation schemes: Optimal fractionation (black line), best protracted scheme obtained for d = 1.8
Gy (grey line), best hypoprotracted treatment obtained with d = 3.2 Gy (light grey) and standard fractionation (dashed line). In all cases the
range 0.002 < ρ < 0.01 was studied. Pannel (a) shows the TMT as a function of ρ and (b) the value of Δ used for each of the schemes.
https://doi.org/10.1371/journal.pone.0178552.g009
Fig 10. Benefit quantification of the conservative suboptimal treatment,Δsubopt = 6 days, against the standard one for ρ 2 [0.002, 0.01].
https://doi.org/10.1371/journal.pone.0178552.g010
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The benefit, in terms of the time delay of the MT, was always larger than a year for every
virtual tumor. For fast-growing LGGs, this scheme is close to the optimal one. For all the sub-
optimal treatment simulations, it was ensured finishing the treatment before MT occurs, with
same or lower toxicity than the standard one.
Discussion
Mathematical modeling has the potential to help in selecting LGGs patients who may benefit
from RT and in developing specific optimal fractionation schemes for selected patient sub-
groups. Many papers have developed mathematical models of response of gliomas to RT [31–
38, 40]. However, the mathematical study of what is the optimal RT course for LGGs has
received little attention [39].
Our results show that a substantial delay of the MT could be achieved by using non-stan-
dard fractionation regimes such as metronomic, protracted or hypoprotracted schemes. In all
cases the toxicity of the usual scheduling computed using the LQ model was preserved. Metro-
nomic fractionations were found to be the ones delaying the most the MT. These schemes
were also robust leading to survival gains when the time between RT fractions was chosen to
be sub-optimal.
In order to limit the total number of doses to a reasonable limit the minimal dose per frac-
tion was fixed to be 0.5 Gy. However, the optimal inter-spacing time was dependent on the
tumor growth rate: being 6 days for fast-growing LGGs and 16 days for slowly-growing LGG.
Intuitively what the optimization scheme does is to let the tumor grow in size and treat it
when it is close to the transformation density. Thus it is based on the idea that larger tumors
have slower growth rates. This strategy may be useful for this kind of slowly-growing tumors
that do not metastatize. In contrast, classical intensive treatment strategies take the tumor to a
dynamical region where it regrows faster because of the accelerated repopulation phenomenon
(i.e. the exponential growth of the logistic equation for small densities).
In addition to this phenomenon there is another one not accounted for in our paper. Not
only the tumor grows slowly as a whole but also very few cells are proliferating in a LGG. Thus
intensive therapies target only a small subset of the tumor’s population that is active for the 6
weeks of treatment. Fractionation schemes with fractions well-separated in time could target
different tumor cells subpopulations and be substantially more effective what would add an
extra improvement to the results found in this paper.
It is interesting that, in our in-silico approach, both fast- and slowly-growing LGG benefited
from the metronomic therapy although slowly-growing LGGs experienced a larger advantage.
For fast-growing LGGs, suffering the transformation earlier, the delay in MT was always
found to be larger than one year. For slowly-growing LGGs the survival benefit was substantial,
even of six years for the smallest values of the proliferation rate used, ρ = 0.002 day−1.
Some delay in the MT can be expected by choosing a conservative scheduling (i.e. applying
the optimal strategy for fast-growing LGGs to all tumors). Tailoring the treatment to individ-
ual patients requires having some information on the tumor growth rate. It was proposed that
a way of getting that information would be to probe the LGG with a small amount of RT [37].
A different possibility would be to use data from pathology, such as Ki67 or MIB-1 labeling
indexes when available. However, this information is dependent on the tumor sample taken
and may lead to a proliferation rate underestimation. Also since the decision on using RT is
taken some time after the surgery there is no guarantee that original proliferation indexes
would be representative of the tumor biology.
Since knowing the exact tumor behavior and parameters for each patient may be beyond
reach with current technology, a personalized optimal therapy may be complicated nowadays.
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However, a conservative suboptimal scheme might provide at least an extra year delay to MT
compared to the standard treatment for all patients. This suggested scheme is optimal for
patients with fast-growing LGG tumors and consists of the use of low doses (d = 0.5 Gy) and
distances between doses of Δ = 6 days. All virtual patients treated with the conservative subop-
timal scheme finished the treatment before malignant transformation and obtained same or
lower toxicity than the patients that received the standard RT care.
Protracted therapies seem to be more effective than hypoprotracted ones for all virtual
tumors but hypoprotracted therapies considerably reduce the number of doses per patient.
This has two practical advantages: (i) patients attend the hospital less times allowing them to
follow their normal life, (ii) RT machines can be more available allowing the clinicians to
attend more patients. The disadvantage is that if the inter spacing between doses is big enough,
it may be necessary to recalculate the RT plans for each patient.
From a practical point of view, the increase in the number of patient’s visits to the hospital
to receive a large number of RT sessions, as required by metronomic schedules, poses practical
problems. The obvious first one is the personal inconvenience of getting to the hospital every
week or every other week for extended periods of time, which would substantially increase the
cost of treatment. However, given that LGGs are not frequent diseases and the large potential
survival gains, the costs should be balanced with the treatment potential advantages.
The fact that low-dose therapies maintained for long times are found to be optimal raises
the question of the potential use of brachytherapy beads to treat gliomas. In fact, some limited
experiences point to very satisfactory results of iodine-125 in children with inoperable gliomas
[49], LGG located in the central sulcus region [50] or large LGG patient cohorts [51] although
prospective randomized studies are missing. Other studies reported results similar to those
obtained with external beam RT [52]. Brachytherapy implies a decaying dose, typically of
exponential form d(t) and thus requires a separate mathematical modeling. We plan to per-
form the analysis in the future.
Another implication of our work is that therapies that increase the critical cell density U⇤
might provide a benefit when combined with cytotoxic therapies such as RT. Since malignant
transformation seems to be related to the development of hypoxia, necrosis and changes on
tumor vasculature, we hypothesize that therapies targeting thrombotic events [24] could increase
U⇤ and provide a synergistic benefit when combined with the optimal strategies discussed here.
Also antiangiogenic therapies may be helpful to defer the MT once the critical density is
reached by blocking the development of tumor vessels. Indeed, it has been reported that the
combination of bevacizumab + irinotecan appears to produce sustained disease control in
some children with recurrent LGGs [53].
Finally, our findings may be also applicable to chemotherapy treatment, since despite the
different ways of killing the cells, cytotoxic therapies such as the standard chemotherapeutical
drug for LGGs, temozolomide, mainly damages DNA during mitosis. Indeed a model based
on previous ideas for RT [39] has been recently developed providing an excellent description
of the response of individual LGG patients to temozolomide [54]. Recent observations using
vinblastine with a limited number of LGG patients may be related to our analysis [55], their
observations suggest the use of a metronomic chemotherapy with weekly vinblastine after an
induction by irinotecan-bevacizumab in order to improve progression-free survival in chil-
dren with LGG.
Conclusion
The goal of our study was to develop a mathematical methodology allowing to find the param-
eters of the radiation protocol delaying the most the TMT of LGGs.
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The optimal fractionation scheme was found to be a metronomic one in all the situations
studied where small fractions of radiations (in our case the minimal allowed one was d = 0.5
Gy) with moderate separations between fractions of several days were given for very long peri-
ods of time. The choice of metronomic schemes was shown to potentially delay the malignant
transformation for variable times ranging from 1 to 6 years depending on the tumor’s growth
parameters. The time between fractions was also found to depend strongly on the proliferation
rate of each virtual tumor.
We studied also other types of fractionations which might be more applicable in clinical
practice, such as protracted or hypoprotracted schemes. They were also found to provide a
substantial delay of the time to the malignant transformation when compared with standard
schemes.
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santa LA. Delay effects in the response of low-grade gliomas to radiotherapy: A mathematical model
and its therapeutical implications. Mathematical Biology and Medicine. 2015; 32:307–329. https://doi.
org/10.1093/imammb/dqu009 PMID: 24860116
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